Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Celltrion Wins Italian Steqeyma® Supply Contracts

Aug 12, 2025

On 12 August 2025, Celltrion announced that it has been awarded a series of supply contracts in Italy for its autoimmune disease therapies and oncology treatments.  Key contracts include additional contracts for Steqeyma®, biosimilar to J&J/Janssen’s Stelara® (ustekinumab), in the Veneto, Trentino-Alto Adige, and Sardinia regions, following contracts for four regions earlier this year.  This means that Celltrion will now supply Steqeyma® to seven regions in total through to May 2026.

Steqeyma® was approved in Europe in August 2024, following a positive CHMP opinion in June 2024.  Celltrion launched Steqeyma® in Italy in mid-January 2025, with Celltrion confirming on 23 January 2025 that it had completed the launch of Steqeyma® in Italy, France, Spain, the UK, and Germany.  Celltrion was the third company to launch an ustekinumab biosimilar in Europe.

On 22 July 2024, STADA and Alvotech announced the launch of biosimilar ustekinumab Uzpruvo® across the majority of European countries.  This was quickly followed by Sandoz announcing the European launch of Pyzchiva® on 25 July 2024.